Celldex Therapeutics, Inc. $CLDX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 40.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 547,667 shares of the biopharmaceutical company’s stock after selling 369,741 shares during the period. Pictet Asset Management Holding SA’s holdings in Celldex Therapeutics were worth $17,750,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Odyssean LLC purchased a new position in shares of Celldex Therapeutics in the second quarter worth about $3,538,000. Quantinno Capital Management LP boosted its holdings in shares of Celldex Therapeutics by 178.7% in the first quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company’s stock worth $2,085,000 after acquiring an additional 42,158 shares during the period. Engineers Gate Manager LP purchased a new position in Celldex Therapeutics during the 2nd quarter valued at about $1,259,000. Bank of America Corp DE increased its position in shares of Celldex Therapeutics by 70.8% during the first quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company’s stock valued at $22,478,000 after buying an additional 293,759 shares during the period. Finally, Sei Investments Co. purchased a new stake in shares of Celldex Therapeutics in the first quarter worth about $1,210,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Stifel Nicolaus set a $68.00 target price on Celldex Therapeutics in a research report on Tuesday, September 22nd. Morgan Stanley increased their price target on shares of Celldex Therapeutics from $57.00 to $61.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Thursday, October 15th. Guggenheim lifted their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Barclays upped their price objective on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.08.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $28.53 on Friday. Celldex Therapeutics, Inc. has a fifty-two week low of $22.33 and a fifty-two week high of $45.14. The business has a 50 day moving average price of $32.19 and a 200-day moving average price of $32.75.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.06. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.72 million. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.